207 related articles for article (PubMed ID: 24743707)
21. Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma.
Digifico E; Erreni M; Mannarino L; Marchini S; Ummarino A; Anfray C; Bertola L; Recordati C; Pistillo D; Roncalli M; Bossi P; Zucali PA; D'Incalci M; Belgiovine C; Allavena P
Front Immunol; 2023; 14():1116430. PubMed ID: 37398648
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.
Kurai J; Chikumi H; Hashimoto K; Takata M; Sako T; Yamaguchi K; Kinoshita N; Watanabe M; Touge H; Makino H; Igishi T; Hamada H; Yano S; Shimizu E
Int J Oncol; 2012 Nov; 41(5):1610-8. PubMed ID: 22922885
[TBL] [Abstract][Full Text] [Related]
23. Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma.
Otsuki T; Nakashima T; Hamada H; Takayama Y; Akita S; Masuda T; Horimasu Y; Miyamoto S; Iwamoto H; Fujitaka K; Miyata Y; Miyake M; Kohno N; Okada M; Hattori N
Eur Respir J; 2018 May; 51(5):. PubMed ID: 29519924
[TBL] [Abstract][Full Text] [Related]
24. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors.
Inamoto T; Yamada T; Ohnuma K; Kina S; Takahashi N; Yamochi T; Inamoto S; Katsuoka Y; Hosono O; Tanaka H; Dang NH; Morimoto C
Clin Cancer Res; 2007 Jul; 13(14):4191-200. PubMed ID: 17634548
[TBL] [Abstract][Full Text] [Related]
25. FK228 suppress the growth of human malignant pleural mesothelioma tumor independent to epithelioid or non-epithelioid histology.
Chan JM; Chang YC; Chan HC; Chan HC; Chang WC; Wang LF; Tsai TH; Chen YJ; Huang WC
Mol Med; 2024 May; 30(1):73. PubMed ID: 38822233
[TBL] [Abstract][Full Text] [Related]
26. M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.
Chaouche-Mazouni S; Copin MC; Lassalle P; Lebaili N; Cortot A; Scherpereel A
In Vivo; 2013; 27(2):227-32. PubMed ID: 23422483
[TBL] [Abstract][Full Text] [Related]
27. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
Okita R; Shimizu K; Nojima Y; Yukawa T; Maeda A; Saisho S; Nakata M
Oncol Rep; 2015 Dec; 34(6):2864-70. PubMed ID: 26503698
[TBL] [Abstract][Full Text] [Related]
28. Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.
Volta V; Ranzato E; Martinotti S; Gallo S; Russo MV; Mutti L; Biffo S; Burlando B
PLoS One; 2013; 8(3):e58051. PubMed ID: 23526965
[TBL] [Abstract][Full Text] [Related]
29. Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
Maehara S; Usuda J; Ishizumi T; Ichinose S; Ohtani K; Inoue T; Imai K; Furumoto H; Kudo Y; Kajiwara N; Ohira T; Ikeda N
Int J Oncol; 2015 Feb; 46(2):741-9. PubMed ID: 25385189
[TBL] [Abstract][Full Text] [Related]
30. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
31. Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System.
Tabata C; Tabata R; Nakano T
Asian Pac J Cancer Prev; 2016; 17(7):3405-9. PubMed ID: 27509983
[TBL] [Abstract][Full Text] [Related]
32. Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription.
Yamada K; Hayashi M; Madokoro H; Nishida H; Du W; Ohnuma K; Sakamoto M; Morimoto C; Yamada T
PLoS One; 2013; 8(4):e62304. PubMed ID: 23638030
[TBL] [Abstract][Full Text] [Related]
33. UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
Reardon ES; Shukla V; Xi S; Gara SK; Liu Y; Straughan D; Zhang M; Hong JA; Payabyab EC; Kumari A; Richards WG; De Rienzo A; Hassan R; Miettinen M; Xi L; Raffeld M; Uechi LT; Li X; Wang R; Chen H; Hoang CD; Bueno R; Schrump DS
J Thorac Oncol; 2021 Jan; 16(1):89-103. PubMed ID: 32927122
[TBL] [Abstract][Full Text] [Related]
34. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
[TBL] [Abstract][Full Text] [Related]
35. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
36. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
Raphael J; Le Teuff G; Hollebecque A; Massard C; Bahleda R; Margery J; Besse B; Soria JC; Planchard D
Lung Cancer; 2014 Aug; 85(2):251-7. PubMed ID: 24882384
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
Laurie SA; Hao D; Leighl NB; Goffin J; Khomani A; Gupta A; Addison CL; Bane A; Seely J; Filion ML; Pond GR; Levine MN
Lung Cancer; 2017 Feb; 104():65-69. PubMed ID: 28213002
[TBL] [Abstract][Full Text] [Related]
39. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
[TBL] [Abstract][Full Text] [Related]
40. Repurposing therapeutics for malignant pleural mesothelioma (MPM) - Updates on clinical translations and future outlook.
Kulkarni NS; Gupta V
Life Sci; 2022 Sep; 304():120716. PubMed ID: 35709894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
